Knowledge sharing as a social dilemma in pharmaceutical innovation

Food and Drug Law Journal

Volumn 71, Issue 4, 2016, Pages 673-709

  Kim, Daria ^a  

^a UNIVERSITY OF AUGSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; EVIDENCE BASED MEDICINE; HUMAN; INVESTMENT; KNOWLEDGE MANAGEMENT; MEDICAL RESEARCH; PATENT; STANDARDIZATION; ECONOMIC ASPECT; INFORMATION DISSEMINATION; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; ECONOMIC COMPETITION; HUMANS; INFORMATION DISSEMINATION; UNITED STATES;

EID: 85031726444     PISSN: 1064590X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (160)

1. Dennis Castro, The Albert Einstein Handbook - Everything you Need to Know About Albert Einstein 14 (2016).
2. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/11/WC500099473.pdf (last visited Aug. 26, 2016).
3. European Medicines Agency, The European Medicines Agency Policy on Publication of Clinical Data for Medicinal Products for Human Use, EMA/240810/2013, 4 (Oct. 2, 2014).
4. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2014/10/WC500174796.pdf (last visited Aug. 26, 2016).
5. European Medicines Agency, Publication and Access to Clinical Data: An Inclusive Development Process (2014), http://www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/general/general-content-000556.jsp (last visited Aug. 24, 2016).
6. http://www.ema.europa.eu/docs/en-GB/document-library/Overview-of-comments/2014/09/WC500174225.pdf.
7. U.S. Chamber of Commerce & Global Intellectual Property Center, Heading in a Different Direction? The European Medicines Agency's Policy on the Public Release of Clinical Trials Data 15, 27 (2014), http://www.theglobalipcenter.com/wp-content/uploads/2014/05/EMA-Study-COMPLETE.pdf (last visited Aug. 24, 2016).
8. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2014/10/WC500174767.pdf (last visited Aug. 26, 2016).
9. http://www.ombudsman.europa.eu/cases/decision.faces/en/68107/html.bookmark (last visited Aug. 26, 2016).
10. http://www.nationalacademies.org/hmd/Reports/2015/Sharing-Clinical-Trial-Data.aspx (last visited Aug. 25, 2016).
11. The World Health Organization, WHO Statement on Public Disclosure of Clinical Trial Results, 3, http://www.who.int/ictrp/results/WHO-Statement-results-reporting-clinical-trials.pdf?ua=1 (last visited Aug. 26, 2016).
12. Jerome H. Reichman, Rethinking the Role of Clinical Trial Data in International Intellectual Property Law: The Case for a Public Goods Approach, 13 MARQ. INTELL. PROP. L. REV. 49-52 (2009).
13. Antony Taubman, Unfair Competition and the Financing of Public Knowledge Goods: The Problem of test data protection, 3 J. INTELL. PROP. L. & PRAC. 591 (2008).
14. Tracy R. Lewis, Jerome H. Reichman & Anthony D. So, The Case for Public Funding and Public Oversight of Clinical Trials, 4 ECONOMISTS' VOICE 1 (2007).
15. W. A. Ray & C. M. Stein, Reform of Drug Regulation - Beyond an Independent Drug-Safety Board, 354 NEW ENG. J MED. 194, 196-99 (2006).
16. Trudo Lemmens, Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene, 32 J. L. MED. & ETHICS 641, 643-45 (2004).
17. Uwe E. Reinhardt, An Information Infrastructure for the Pharmaceutical Market, 23 HEALTH AFF. 107, 109 (2004).
18. Marcia Angell, The Clinical Trials Business: Who Gains?, BUYING IN OR SELLING OUT? THE COMMERCIALIZATION OF THE AMERICAN RESEARCH 127-32 (D. G. Stein ed., 2004).
19. Thomas O. McGarity & Sidney A. Shapiro, The Trade Secret Status of Health and Safety Testing Information: Reforming Agency Disclosure Policies, 93 HARV. L. REV. 837, 839 (1980).
20. Rebecca S. Eisenberg, Data Secrecy in the Age of Regulatory Exclusivity, THE LAW AND THEORY OF TRADE SECRECY 467, 491 (Rochelle C. Dreyfuss & Katherine J. Strandburg eds., 2011).
21. Mustafa Ünlü, It Is Time: Why FDA Should Start Disclosing Drug Trial Data, 16 MICH. TELECOMM. TECH. L. REV. 511, 545 (2010).
22. Trudo Lemmens & Candice Telfer, Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency, 38 AM. J.L. &MED. 63, 66 (2012).
23. Trudo Lemmens, Pharmaceutical Knowledge Governance: A Human Rights Perspective, 41 J.L. MED. & ETHICS 163, 164-172 (2013).
24. Janene Boyce, Disclosure of Clinical Trial Data: Why Exemption 4 of the Freedom of Information Act Should Be Restored, 4 DUKE L. & TECH. REV. 1, (2005).
25. http://www.ncbi.nlm.nih.gov/books/NBK22942/pdf/Bookshelf-NBK22942.pdf.
26. Julio S G Montaner, Michael V O'Shaughnessy & Martin T Schechter, Industry-sponsored clinical research: A double-edged sword, 358 THE LANCET 1893, 1894 (2001).
27. Joel Lexchin et al., Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review, 326 BRIT.MED. J. 1167, 1170 (2003).
28. Mark A. Rodwin, Independent Clinical Trials to Test Drug: The Neglected Reform, 6 ST. LOUIS U. J. HEALTH L. & POL'Y 113, 113 (2013).
29. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E3/E3-Guideline.pdf.
30. Erika Lietzan, A New Framework for Assessing Clinical Data Transparency Initiatives, 18 MARQ. INTELL. PROP. L. REV. 33, 37 (2014).
31. http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2016/03/WC500202621.pdf;.
32. http://www.ema.europa.eu/docs/en-GB/document-library/Overview-of-comments/2014/09/WC500174224.pdf.
33. http://www.ema.europa.eu/docs/en-GB/document-library/Overview-of-comments/2014/09/WC500174222.pdf.
34. Mark J. Scheineson & M. Lynn Sykes, Major New Initiatives Require Increased Disclosure of Clinical Trial Information, 60 FOOD & DRUG L.J. 525, 525 (2005).
35. Elinor Ostrom, A Behavioral Approach to the Rational Choice Theory of Collective Action, in CHOICE, RULES AND COLLECTIVE ACTION: THE OSTROMS ON THE STUDY OF INSTITUTIONS AND GOVERNANCE 121, 122 (Filippo Sabetti & Paul Dragos Aligica eds., 2014).
36. Elinor Ostrom, GOVERNING THE COMMONS: THE EVOLUTION OF INSTITUTIONS FOR COLLECTIVE ACTION 5 (2011).
37. Julie De Coninck, Behavioural Economics and Legal Research, in METHODOLOGIES OF LEGAL RESEARCH, 257, 272-73 (Mark Van Hoecke ed., 2011).
38. https://www.wto.org/english/res-e/booksp-e/analytic-index-e/trips-03-e.htm#article39.
39. http://www.ip.mpg.de/de/projekte/details/the-role-of-competition-law-inregulating-access-to-clinical-trial-data-in-the-context-of-competition-in-innovation-in-the-pharmaceuticalsector.html (last visited Aug. 27, 2016).
40. Josef Drexl, Intellectual Property in Competition: How to Promote Dynamic Competition as a Goal, in MORE COMMON GROUND FOR INTERNATIONAL COMPETITION LAW 210, 215-17 (Josef Drexl et al. eds., 2011).
41. David W. Barnes, The Incentives/Access Tradeoff, 9 NW. J. TECH. & INTELL. PROP. 96, 97-99 (2010).
42. Josef Drexl, IMS-Health and Trinko - Antitrust Placebo for Consumers Instead of Sound Economics in Refusal-to-Deal Cases, 35 INT'L REV. INTELL. PROP. & COMPETITION L. 788, 790 (2004).
43. Massimo Motta, COMPETITION POLICY: THEORY AND PRACTICE 55, 56-57 (2004).
44. Joseph Farell & Michael Katz, The Effects of Antitrust and Intellectual Property Law on Compatibility and Innovation, 43 ANTITRUST BULL. 609, 612 (1998).
45. William S. Comanor, The Political Economy of the Pharmaceutical Industry, 24 J. ECON. LIT. 1178, 1180 (1986).
46. Paul A. Samuelson, The Pure Theory of Public Expenditure, 36 REV. ECON. & STAT. 387 (1954).
47. Joseph E. Stiglitz, Knowledge as a Global Public Good, GLOBAL PUBLIC GOODS: INTERNATIONAL COOPERATION IN THE 21ST CENTURY 308 (I. Kaul, I. Grunberg & M. A. Stern eds., 1999).
48. Richard A. Musgrave, Provision for Social Goods, in Public Economics: An Analysis of Public Production and Consumption and Their Relations to the Private Sectors 124-45 (Julius Margolis & H. Guitton eds. 1969).
49. Richard A. Musgrave, THE Theory of Public Finance; A Study in Public Economy 43-44 (1959).
50. Robert P. Merges, Peter S. Menell & Mark A. Lemley, Intellectual Property in the New Technological Age 10, 11-12 (2003).
51. David Blumenthal, Characteristics of a Public Good and How They Are Applied to Healthcare Data, in Clinical Data as the Basic Staple 140, 142 (A.W. Goodby, L. Olsen & M. McGinnis eds., 2010).
52. Inge Kaul et al., Defining Global Public Goods, in Global Public Goods: International Cooperation in the 21ST Century 2, 4 (Inge Kaul, Isabelle Grunberg & Mark A. Stern eds., 1999).
53. Charles Edquist, Systems of Innovation Approaches - Their Emergence and Characteristics, in Systems of Innovation Technologies, Institutions and Organizations 10-12 (Ch. Edquist ed., 2006).
54. Mark A. Lemley, The Surprising Virtues of Treating Trade Secrets as IP Rights, in The Law And Theory of Trade Secrecy: A Handbook of Contemporary Research 109, 122-23 (Rochelle C. Dreyfuss & Katherine J. Strandburg eds., 2011).
55. Michael Risch, Trade Secret Law and Information Development Incentives, in the Law and Theory of Trade Secrecy: A Handbook of Contemporary Research 152, 154 (Rochelle C. Dreyfuss & Katherine J. Strandburg eds., 2011).
56. David D. Friedman, William M. Landes & Richard A. Posner, Some Economics of Trade Secret Law, 5 J. ECON. PERSP. 61, 62 (1991).
57. Robert G. Bone, A New Look at Trade Secret Law: Doctrine in Search of Justification, 86 CALIF. 241, 264-72 (1998).
58. Richard C. Levin et al., Appropriating the Returns from Industrial Research & Development, 18 BROOKINGS PAPERS ECON. ACTIVITY 783-832 (1987).
59. https://www.brookings.edu/bpeaarticles/appropriating-the-returns-from-industrial-research-and-development/.
60. Richard B. Stewart, Regulation, Innovation, and Administrative Law: A Conceptual Framework, 69 CALIF. 1256, 1260 (1981).
61. Rebecca S. Eisenberg, The Role of FDA in Innovation Policy, 13 MICH. TELECOMM. TECH. L. REV. 345, 371 (2007).
62. Ariel Katz, Pharmaceutical Lemons: Innovation and Regulation in the Drug Industry, 14 MICH. TELECOMM. TECH. L. REV. 1, 11 (2007).
63. George A. Akerlof, The Markets for 'Lemons': Qualitative Uncertainty and the Market Mechanism, 84 Q. J. ECON. 488, 488 (1970).
64. Evan R. Kwerel, Economic Welfare and the Production of Information by a Monopolist: The Case of Drug Testing, 11 BELL J. ECON. 505, 506 (1980).
65. Luigi Orsenigo, Giovanni Dosi & Mariana Mazzucato, The Dynamics of Knowledge Accumulation, Regulation, and Appropriability in the Pharmabiotech Sector: Policy Issues, in Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech 402, 406-08 (Mariana Mazzucato & Giovanni Dosi eds., 2006).
66. http://apps.who.int/iris/bitstream/10665/44576/1/9789241501453-eng.pdf.
67. http://www.ifpma.org/wp-content/uploads/2016/01/IFPMA-2011-Data-Exclusivity-En-Web.pdf.
68. http://www.ema.europa.eu/docs/en-GB/document-library/Overview-of-comments/2014/09/WC500174225.pdf.
69. http://www.ema.europa.eu/docs/en-GB/document-library/Overview-of-comments/2014/09/WC500174222.pdf.
70. Arvind K. Bansal & Vishal Koradia, The Role of Reverse Engineering in the Development of Generic Formulations, PHARM. TECH., Aug. 2005, http://www.pharmtech.com/role-reverse-engineeringdevelopment-generic-formulations.
71. Joseph A. DiMasi & Cherie Paquette, The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development, 22 PHARMACOECONOMICS 1, 2 (2004).
72. Joseph A. DiMasi et al., Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs, 47 J. HEALTH ECON. 20, 20 (2016).
73. Joseph DiMasi et al., The Price of Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 151 (2003).
74. Richard E. Rowberg, CONG. RESEARCH SERV., RL30913, Pharmaceutical Research and Development: A Description and Analysis of the Process (2001).
75. Denise T. Resnik, Clinical Research from the Industry Perspective, in Principles & Practice of Clinical Research 391, 396 (John I. Gallin & Frederick P. Ognibene eds., 2007).
76. James Bessen & Michael J. Meurer, Lessons for Patent Policy from Empirical Research on Patent Litigation 10, 26-27.
77. Richard C. Levin et al., Appropriating the Returns from Industrial Research and Development 796 (Brookings Institution, Brookings Papers on Economic Activity No. 3, 1987).
78. Edwin Mansfield, Patents and Innovation: An Empirical Study, 32 MGMT. SCI. 173, 175 (1986).
79. Valerie Junod, Drug Marketing Exclusivity Under the United States and European Union Law, 59 FOOD & DRUG L. J. 479, 480 (2008).
80. Trevor Cook, Data Protection and Market Exclusivities for Pharmaceuticals in the EU, 16 PHARMACEUTICALS POL'Y & L. 19, 20 (2014).
81. Suzanne Scotchmer, Incentives to Innovate, in the New Palgrave Dictionary of Economics and the Law 273, 273-76 (Peter Newman ed., 1998).
82. Suzanne Scotchmer, The Political Economy of Intellectual Property Treaties, 20 J. L. ECON & ORG. 415, 422 (2004).
83. Garrett Hardin, The Tragedy of the Commons, 162 SCIENCE 1243, 1243-48 (1968).
84. David Feeny et al., The Tragedy of the Commons: Twenty-Two Years Later, 18 HUM. ECOLOGY 1, 3 (1990).
85. Roy Gardner et al., Social Capital and Cooperation: Communication, Bounded Rationality, and Behavioral Heuristics, in Social Dilemmas & Cooperation 375, 375-411 (Ulrich Shultz, Wulf Albers & Ulrich Mueller eds., 1994).
86. Anisha Shankar & Charles Pavitt, 2 REV. COMM. 251, 257 (2002).
87. Kimberly A. Wade-Benzoni et al., Egocentric Interpretations of Fairness in Asymmetric, Environmental Social Dilemmas: Explaining Harvesting Behavior & The Role of Communication, 67 ORG'L BEHAVIOR& HUM. DECISION PROCESSES 111, 111 (1996).
88. Michael A. Heller, The Tragedy of the Anticommons: Property in the Transition from Marx to Markets, 111 HARV. L. REV. 621, 622 (1998).
89. Frank Michelman, Ethics, Economics, & the Law of Property, 39 TULSA L. REV. 663, 670 (2003).
90. Jetta Frost & Michèle Morner, Overcoming Knowledge Dilemmas: Governing the Creation, Sharing & Use of Knowledge Resources, 2 INT'L J. STRATEGIC CHANGE MGMT 172, 178 (2010).
91. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in Biomedical Research, 280 SCIENCE 698, 698 (1998).
92. Charlotte Hess & Elinor Ostrom, Introduction: An Overview of the Knowledge Commons, in Understanding Knowledge as a Commons: From Theory to Practice 3, 11 (Charlotte Hess & Elinor Ostrom eds., 2007).
93. Kenneth Arrow, Economic Welfare and the Allocation of Resources for Invention, in THE RATE AND DIRECTION OF INVENTIVE ACTIVITY: ECONOMIC AND SOCIAL FACTORS 609, 618 (National Bureau of Economic Research ed., 1962).
94. http://www.nber.org/chapters/c2144.
95. Basil Achilladelis & Nicholas Antonakis, The Dynamics of Technological Innovation: The Case of the Pharmaceutical Industry, 30 RES. POL'Y 535, 574 (2001).
96. https://clinicaltrials.gov/ct2/about-studies/learn.
97. C. Fitz-Gibbon, What's All This About 'Evidence'? Learning and Skills Research 27-29 (2001).
98. https://clinicaltrials.gov/ct2/about-studies/learn (last visited May 17, 2016).
99. C. Fitz-Gibbon, What's All This About 'Evidence'? 5 LEARNING AND SKILLS RESEARCH 1, 27-29 (2001).
100. http://www.biochemistry.org/Portals/0/Education/Docs/Pharmacology%20Skills%20for%20Drug%20Discovery.pdf.
101. Harry M. Collin, The Meaning of Data: Open & Closed Evidential Cultures in the Search for Gravitational Waves, 104 AMERICAN J. SOCIOLOGY 293, 294 (1998).
102. Robert K. Merton, THE SOCIOLOGY OF SCIENCE: THEORETICAL & EMPIRICAL INVESTIGATIONS (1973).
103. Thomas H. Davenport & Laurence Prusak, Working Knowledge 6 (1998).
104. Max Boisot & Agustí Canals, Data, Information & Knowledge: Have We Got It Right?, 14 J. EVOLUTIONARY ECON. 43, 43-67 (2004).
105. Dana Dalrymple, Scientific Knowledge as a Global Public Good: Contributions to Innovation & the Economy, THE ROLE OF SCIENTIFIC & TECHNICAL DATA AND INFORMATION IN THE PUBLIC DOMAIN: PROCEEDINGS OF A SYMPOSIUM 35, 35 (National Academy of Sciences ed., 2003).
106. http://www.phrma.org/sites/default/files/pdf/PhRMAPrinciplesForResponsibleClinicalTrialDataSharing.pdf.
107. Harlan M. Krumhollz et al., Sea Change in Open Science and Data Sharing: Leadership by Industry, 7 CIRCULATION: CARDIOVASCULAR QUALITY &OUTCOMES 499, 499-504 (2014).
108. Roche, Roche Global Policy on Sharing of Clinical Trials Data 1 (2013), https://web.archive.org/web/20160623230707/http://rochetrials.com/pdf/RocheGlobalDataSharingPolicy.pdf.
109. Ramzi Suleiman et al., Fixed Position and Property Rights in Sequential Resource Dilemmas under Uncertainty, 93 ACTA PSYCHOLOGICA 229, 230-31 (1996).
110. Anders Biel & Tommy Gärling, The Role of Uncertainty in Resource Dilemmas, 15 J.ENVTL. PSYCHOL. 221, 221-33 (1995).
111. David V. Budescu, Amnon Rapoport, & Ramzi Suleiman, Resource Dilemmas with Environmental Uncertainty and Asymmetric Players, 20 EUR. J. SOC. PSYCHOL., 475 (1990).
112. David V. Budescu et al., Common Pool Resource Dilemmas under Uncertainty: Qualitative Test of Equilibrium Solutions, 10 GAMES & ECON. BEHAV. 171, 173-76 (1995).
113. Paul Nightingale & Surya Mahdi, The Evolution of Pharmaceutical Innovation, in KNOWLEDGE ACCUMULATION &INDUSTRY EVOLUTION: THE CASE OF PHARMA-BIOTECH 73, 73 (Mariana Mazzucato & Giovanni Dosi eds., 2006).
114. W. Nicholson Price II & Timo Minssen, Will clinical trial data disclosure reduce incentives to develop new uses of drugs?, 33 NATURE BIOTECHNOLOGY 685, 686 (2015).
115. Harlan M. Krumholz et al., Sea Change in Open Science and Data Sharing Leadership by Industry, 7 CIRCULATION: CARDIOVASCULAR QUALITY &OUTCOMES 499, 502 (2014).
116. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/general/general-content-000555.jsp.
117. http://www.cdc.gov/maso/Policy/ReleasingData.pdf.
118. http://mrctcenter.org/wp-content/uploads/2015/11/2014-10-1-harvard-mrct-brief-of-mrct-on-bill-c-17.pdf.
119. Robyn M. Dawes, Social Dilemmas, 31 ANN. REV. PSYCHOL. 169, 169 (1980).
120. Tom Dedeurwaerdere, The Role of Law, Institutions and Governance in Facilitating Access to the Scientific Research Commons: A Philosopher's Perspective, GENE PATENTS AND COLLABORATIVE LICENSING MODELS; PATENT POOLS, CLEARINGHOUSES, OPEN SOURCE MODELS AND LIABILITY REGIMES 365, 368 (Geertrui Van Overwalle, ed. 2009).
121. Joseph A. Di Masi & Cherie Paquette, The Economics of Follow-on Drug Research and Development: Trends in Entry Rates and the Timing of Development, 22 PHARMACOECONOMICS 1, 12 (2004).
122. Michael Lanthier, Kathleen L. Miller, Clark Nardinelli, & Janet Woodcock, An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011, 32 HEALTH AFFAIRS 1433, 1434-36 (2013).
123. Carl V. Patton & David S. Sawicki, Basic Methods of Policy Analysis & Planning 227 (1986).
124. Harold Demsetz, The Private Production of Public Goods, 13 J.L. &ECON. 293, 295 (1970).
125. Catrin Tudur Smith et al., Sharing Individual Participant Data from Clinical Trials: An Opinion Survey Regarding the Establishment of a Central Repository, 9 PUB. LIBR. SCI. 1, 4-5 (2014).
126. Barry Bozeman & Juan D. Rogers, A Churn Model of Scientific Knowledge Value: Internet Researchers as a Knowledge Value Collective, 31 RES. POL'Y 769, 774-80 (2002).
127. Franco Malerba & Luigi Orsenigo, Innovation and Market Structure in the Dynamics of the Pharmaceutical Industry and Biotechnology: Towards a History-Friendly Model, 11 INDUSTRIAL & CORPORATE CHANGE 667, 671-72 (2002).
128. Bjorn Johnson, Systems of Innovation: Overview and Basic Concepts, INSTITUTIONS AND ORGANIZATIONS IN SYSTEMS OF INNOVATION 36, 42-43 (Charles Edquist ed., 2006).
129. Charles Edquist, System of Innovation Approaches: Their Emergence and Characteristics, in INSTITUTIONS AND ORGANIZATIONS IN SYSTEMS OF INNOVATION 1, 19 (Charles Edquist ed., 2006).
130. Nirmal Sengupta, Neglected Sources of Irrigation, ECONOMIC STUDIES OF INDIGENOUS AND TRADITIONAL KNOWLEDGE 121, 176 (Nirmal Sengupta ed. 2007).
131. Paul A. David, Intellectual Property Institutions and the Panda's Thumb: Patents, Copyrights, and Trade Secrets in Economic Theory and History, GLOBAL DIMENSIONS OF INTELLECTUAL PROPERTY RIGHTS IN SCIENCE AND TECHNOLOGY 19, 28 (Mitchel B. Wallerstein, Mary Ellen Mogee, & Roberta A. Schoen eds., 1993).
132. Basil Achilladelis & Nicholas Antonakis, The Dynamics of Technological Innovation: The Case of the Pharmaceutical Industry, 30 RES. POL'Y 535, 550 (2001).
133. Rebecca S. Eisenberg, Patents and the Progress of Science: Exclusive Rights and Experimental Use, 56 U.CHI. L. REV. 1017, 1055-56 (1989).
134. Suzanne Scotchmer, Standing on the Shoulders of Giants: Cumulative Research and the Patent Law, 5 J. ECON. PERSP. 29 (1991).
135. R. M. Henderson, L. Orsenigo, & G. Pisano, The Pharmaceutical Industry and the Revolution in Molecular Biology: Exploring the interactions between scientific, institutional, and organizational change, Sources of Industrial Leadership: Studies of Seven Industries 267-311 (D. C. Mowery & R. R. Nelson eds., 1999).
136. Peter C. Gøtzsche, Strengthening and Opening up Health Research by Sharing Our Raw Data, 236, 237 Circ Cardiovasc Qual Outcomes (2012).
137. Sherry Brandt-Rauf, Biomedical Research, The Role of Scientific and Technical Data and Information in the Public Domain: Proceedings of a Symposium 65, 66 (National Academy of Sciences, 2003).
138. Brian Kahin, Patents and Diversity in Innovation, 13 MICH. TELECOMM. & TECH. L REV. 389, 397 (2007).
139. Bryan C. Mercurio, TRIPS-Plus Provisions in FTAs: Recent Trends, in REGIONAL TRADE AGREEMENTS AND THE WTO LEGAL SYSTEM 215, 227 (Lorand Bartels & Frederico Ortino eds., 2006).
140. Partha Dasgupta & Paul A. David, Information Disclosure and the Economics of Science and Technology, in Arrow and the Ascent of Modern Economic Theory 519 (G. R. Feiwel ed., 1987).
141. Roberto Mazzoleni & Richard R. Nelson, The Benefits and Costs of Strong Patent Protection: A Contribution to the Current Debate, 27 RES. POL'Y 273, 273 (1998).
142. Mazzoleni & Nelson, Patents Induce Disclosure and Wide Use of Inventions 278.
143. Jerome H. Reichman & Paul F. Uhlir, A Contractually Reconstructed Research Commons for Scientific Data in a Highly Protectionist Intellectual Property Environment, 66 LAW & CONTEMP. PROBS. 315, 411 (2003).
144. Deepa Varadarajan, Trade Secret Fair Use, 83 FORDHAM L. REV. 1401, 1420 (2014).
145. Peter Doshi & Tom Jefferson, Clinical study reports of randomised controlled trials: An Exploratory Review of Previously Confidential Industry Reports, 3 BMJ OPEN 1, 1 (2013).
146. Peter C. Gøtzsche, Strengthening and Opening Up Health Research by Sharing Our Raw Data, 5 CIRCULATION: CARDIOVASCULAR QUALITY &OUTCOMES 236, 236-37 (2012).
147. Peter Doshi et al., Raw Data from Clinical Trials: Within Reach?, 34 TRENDS PHARMA. SCI. 645, 645-47 (2013).
148. Andrew P. Prayle, Compliance with mandatory reporting of clinical trial results on Clinical Trials.gov: cross sectional study, 344 BIOMEDICAL J. 1, 1 (2012).
149. Robert Cook-Deegan et al., The Next Controversy in Genetic Testing Clinical Data as Trade Secrets?, 21 EUROPEAN J. HUM. GENETICS 585, 585 (2013).
150. Basil Achilladelis & Nicholas Antonakis, The Dynamics of Technological Innovation: The Case of the Pharmaceutical Industry, 30 RES. POL'Y 535, 536 (2001).
151. Graham Cameron, Scientific Data, The Electronic Era, Intellectual Property, IPR (INTELLECTUAL PROPERTY RIGHTS) ASPECTS OF INTERNET COLLABORATIONS, 31, 32 (European Commission, 2001).
152. Philip R. O. Payne, Biomedical Knowledge Integration, 8 PUB. LIBR. SCI. COMPUTATIONAL BIOLOGY 1, 1 (2012).
153. L.A Stewart & M.K.B Parmar, Metaanalysis of the Literature or of Individual Patient Data: Is There a Difference?, 341 THE LANCET 418-22 (1993).
154. F. Koenig et al., Sharing Clinical Trial Data on Patient Level: Opportunities and Challenges, 57 BIOMETRICAL J. 1, 8- 26 (2015).
155. Geertrui Van Overwalle, Governing Genomic Data: Plea for an "Open Commons, " Governing Knowledge Commons 137 (Brett M. Frischmann, Michael J. Madison & Katherine J. Strandburg eds., 2014).
156. Kathrine J. Strandburg, Brett M. Frischmann & Can Cui, The Rare Deceases Clinical Research Network and the Urea Cycle Disorders Consortium as Nested Knowledge Commons, Governing Knowledge Commons 155-208 (Brett M. Frischmann, Michael J. Madison & Katherine J. Strandburg eds., 2014).
157. Charlotte Hess & Elinor Ostrom, Ideas, Artifacts, and Facilities: Information as a Common-pool Resource, 66 LAW & CONTEMPORARY PROBLEMS 111, 121 (2003).
158. Zvi Griliches, The Search for R&D Spillovers, in R&D AND Productivity: The Econometric Evidence 251, 252 (National Bureau of Economic Research, 1998).
159. Mark A. Lemley, Property, Intellectual Property, and Free Riding, 83 TEX L. REV. 1031, 1046 (2005).
160. Ian Ayres & Paul Klemperer, Limiting Patentees' Market Power Without Reducing Innovation Incentives: The Perverse Benefits of Uncertainty and Non-Injunctive Remedies, 97 MICH. L. REV. 985, 987-89 (1999).